Abstract
Objective: To evaluate the efficacy and tolerance of vapreotide, a new somatostatin analogue, in the treatment of refractory AIDS-related diarrhoea. Design: An open, non-comparative pilot trial. Setting: The trial was conducted in 10 medical centres in France. Patients, participants: Thirty-four AIDS patients with chronic diarrhoea unresponsive to conventional antidiarrhoeal therapy were enrolled. Cryptosporidiosis was diagnosed in 21 out of 30 evaluable patients. Mean number of stools prior to therapy was 10.1 ± 4.9 per day (range, 3-20 stools per day). Intervention: After initial baseline studies, patients received subcutaneous vapreotide at escalating doses of 400 (23 patients) or 500 μg (seven patients), between two and six times daily. Main outcome measures: Efficacy was assessed after 14 days of therapy, when it was found to be effective. Responders were offered the opportunity to continue receiving therapy. Results: Four patients demonstrated a complete response and 12 a partial response with > 50% reduction in daily stool emission. Fourteen patients did not respond to doses up to 2400 μg/day. Patients with conditions other than cryptosporidiosis had a significantly higher probability of response (P = 0.013), as did those with milder diarrhoea (<10 stools per day). Median duration of response was 1.5 months (range, 0.5-5 months); relapse occurred in five out of eight responders despite maintenance therapy. Toxicity was minimal. Conclusions: We conclude that AIDS patients with diarrhoea not caused by Cryptosporidium may benefit from vapreotide therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 715-718 |
| Number of pages | 4 |
| Journal | AIDS |
| Volume | 6 |
| Issue number | 7 |
| State | Published - Jul 1 1992 |
| Externally published | Yes |
Fingerprint
Keywords
- Cryptosporidiosis
- Diarrhoea
- Somatostatin analogues
- Vapreotide
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases. / Girard, Pierre Marie; Goldschmidt, Emma; Vittecoq, Daniel; Massip, Patrice; Gastiaburu, Julio; Meyohas, Marie Caroline; Coulaud, Jean Pierre; Schally, Andrew V.
In: AIDS, Vol. 6, No. 7, 01.07.1992, p. 715-718.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases
AU - Girard, Pierre Marie
AU - Goldschmidt, Emma
AU - Vittecoq, Daniel
AU - Massip, Patrice
AU - Gastiaburu, Julio
AU - Meyohas, Marie Caroline
AU - Coulaud, Jean Pierre
AU - Schally, Andrew V
PY - 1992/7/1
Y1 - 1992/7/1
N2 - Objective: To evaluate the efficacy and tolerance of vapreotide, a new somatostatin analogue, in the treatment of refractory AIDS-related diarrhoea. Design: An open, non-comparative pilot trial. Setting: The trial was conducted in 10 medical centres in France. Patients, participants: Thirty-four AIDS patients with chronic diarrhoea unresponsive to conventional antidiarrhoeal therapy were enrolled. Cryptosporidiosis was diagnosed in 21 out of 30 evaluable patients. Mean number of stools prior to therapy was 10.1 ± 4.9 per day (range, 3-20 stools per day). Intervention: After initial baseline studies, patients received subcutaneous vapreotide at escalating doses of 400 (23 patients) or 500 μg (seven patients), between two and six times daily. Main outcome measures: Efficacy was assessed after 14 days of therapy, when it was found to be effective. Responders were offered the opportunity to continue receiving therapy. Results: Four patients demonstrated a complete response and 12 a partial response with > 50% reduction in daily stool emission. Fourteen patients did not respond to doses up to 2400 μg/day. Patients with conditions other than cryptosporidiosis had a significantly higher probability of response (P = 0.013), as did those with milder diarrhoea (<10 stools per day). Median duration of response was 1.5 months (range, 0.5-5 months); relapse occurred in five out of eight responders despite maintenance therapy. Toxicity was minimal. Conclusions: We conclude that AIDS patients with diarrhoea not caused by Cryptosporidium may benefit from vapreotide therapy.
AB - Objective: To evaluate the efficacy and tolerance of vapreotide, a new somatostatin analogue, in the treatment of refractory AIDS-related diarrhoea. Design: An open, non-comparative pilot trial. Setting: The trial was conducted in 10 medical centres in France. Patients, participants: Thirty-four AIDS patients with chronic diarrhoea unresponsive to conventional antidiarrhoeal therapy were enrolled. Cryptosporidiosis was diagnosed in 21 out of 30 evaluable patients. Mean number of stools prior to therapy was 10.1 ± 4.9 per day (range, 3-20 stools per day). Intervention: After initial baseline studies, patients received subcutaneous vapreotide at escalating doses of 400 (23 patients) or 500 μg (seven patients), between two and six times daily. Main outcome measures: Efficacy was assessed after 14 days of therapy, when it was found to be effective. Responders were offered the opportunity to continue receiving therapy. Results: Four patients demonstrated a complete response and 12 a partial response with > 50% reduction in daily stool emission. Fourteen patients did not respond to doses up to 2400 μg/day. Patients with conditions other than cryptosporidiosis had a significantly higher probability of response (P = 0.013), as did those with milder diarrhoea (<10 stools per day). Median duration of response was 1.5 months (range, 0.5-5 months); relapse occurred in five out of eight responders despite maintenance therapy. Toxicity was minimal. Conclusions: We conclude that AIDS patients with diarrhoea not caused by Cryptosporidium may benefit from vapreotide therapy.
KW - Cryptosporidiosis
KW - Diarrhoea
KW - Somatostatin analogues
KW - Vapreotide
UR - http://www.scopus.com/inward/record.url?scp=0026631631&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026631631&partnerID=8YFLogxK
M3 - Article
VL - 6
SP - 715
EP - 718
JO - AIDS
JF - AIDS
SN - 0269-9370
IS - 7
ER -